CRIS Current Research Information System

SOVERINI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.010
AS - Asia 17.807
EU - Europa 13.006
AF - Africa 1.075
SA - Sud America 1.013
OC - Oceania 30
Continente sconosciuto - Info sul continente non disponibili 15
Totale 50.956
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 17.813
VN - Vietnam 5.170
SG - Singapore 4.554
CN - Cina 4.371
GB - Regno Unito 3.801
SE - Svezia 1.839
IT - Italia 1.647
DE - Germania 1.624
HK - Hong Kong 1.137
IN - India 882
FR - Francia 864
BR - Brasile 718
RU - Federazione Russa 658
NL - Olanda 516
IE - Irlanda 472
UA - Ucraina 389
ZA - Sudafrica 335
JP - Giappone 332
TG - Togo 289
KR - Corea 280
EE - Estonia 244
FI - Finlandia 207
CI - Costa d'Avorio 176
CH - Svizzera 168
JO - Giordania 143
AR - Argentina 131
CA - Canada 124
BG - Bulgaria 119
NG - Nigeria 116
PH - Filippine 108
BD - Bangladesh 99
ID - Indonesia 96
GR - Grecia 95
IR - Iran 93
IQ - Iraq 91
BE - Belgio 76
PL - Polonia 69
TR - Turchia 69
TH - Thailandia 68
AT - Austria 61
SC - Seychelles 60
EC - Ecuador 51
TW - Taiwan 51
SA - Arabia Saudita 47
MX - Messico 45
PK - Pakistan 40
ES - Italia 38
UZ - Uzbekistan 29
CZ - Repubblica Ceca 27
MY - Malesia 27
AU - Australia 26
CO - Colombia 23
CL - Cile 22
VE - Venezuela 22
LB - Libano 21
MA - Marocco 20
EG - Egitto 19
AE - Emirati Arabi Uniti 18
PY - Paraguay 17
RO - Romania 16
ET - Etiopia 12
TN - Tunisia 12
LT - Lituania 11
IL - Israele 10
KE - Kenya 10
NP - Nepal 10
PE - Perù 10
PS - Palestinian Territory 10
UY - Uruguay 10
DZ - Algeria 9
RS - Serbia 9
NO - Norvegia 8
SK - Slovacchia (Repubblica Slovacca) 8
EU - Europa 7
HN - Honduras 7
AZ - Azerbaigian 6
KZ - Kazakistan 6
MK - Macedonia 6
OM - Oman 6
QA - Qatar 6
BO - Bolivia 5
DK - Danimarca 5
PA - Panama 5
A2 - ???statistics.table.value.countryCode.A2??? 4
AL - Albania 4
BA - Bosnia-Erzegovina 4
BY - Bielorussia 4
CR - Costa Rica 4
MN - Mongolia 4
PT - Portogallo 4
SY - Repubblica araba siriana 4
XK - ???statistics.table.value.countryCode.XK??? 4
BH - Bahrain 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GY - Guiana 3
HR - Croazia 3
NZ - Nuova Zelanda 3
SV - El Salvador 3
AO - Angola 2
Totale 50.910
Salva come PNG Salva come JPEG
Città #
Southend 3.466
Singapore 3.170
Ashburn 1.813
Fairfield 1.808
Chandler 1.559
Dong Ket 1.250
Hong Kong 1.072
Houston 949
Ho Chi Minh City 934
Woodbridge 923
Wilmington 859
Seattle 822
San Jose 763
Hanoi 731
Beijing 710
Princeton 674
Ann Arbor 648
Cambridge 613
Hefei 519
Dublin 470
Santa Clara 467
Boardman 430
Lauterbourg 337
Nanjing 328
Bologna 312
Westminster 303
Lomé 289
Tokyo 283
Padova 274
Los Angeles 238
New York 211
Seoul 206
Abidjan 175
Helsinki 173
Berlin 167
Dallas 161
Medford 161
Shenyang 158
Jacksonville 153
Jinan 141
Amman 138
Bern 137
Haiphong 135
Redmond 135
Buffalo 132
Saint Petersburg 120
Da Nang 118
Frankfurt am Main 116
Redondo Beach 116
Sofia 116
Nanchang 113
Hebei 109
Milan 109
Changsha 106
Turin 106
San Diego 104
Munich 95
Guangzhou 93
São Paulo 93
Bremen 85
Shanghai 84
Abeokuta 81
Tianjin 81
Brussels 75
Zhengzhou 72
Jiaxing 69
Council Bluffs 65
Florence 65
Falls Church 64
Hangzhou 60
Nuremberg 56
Norwalk 55
Bengaluru 53
Rome 53
London 52
Biên Hòa 51
Johannesburg 51
Orem 49
Haikou 48
Jakarta 48
Toronto 48
Baghdad 47
Mülheim 47
Phoenix 47
Warsaw 46
Redwood City 45
Ningbo 43
Des Moines 42
Taizhou 42
Hải Dương 41
Chicago 39
Falkenstein 39
Can Tho 37
The Dalles 37
Taiyuan 35
Ha Long 34
Thái Nguyên 34
Yubileyny 34
Xi'an 33
Montreal 31
Totale 33.029
Salva come PNG Salva come JPEG
Nome #
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted 656
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 385
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 347
Application of the whole-transcriptome shotgun sequencing approach to the study of Philadelphia-positive acute lymphoblastic leukemia 315
A polymorphism in the chromosome 9p21 ANRIL locus is associated to Philadelphia positive acute lymphoblastic leukemia 302
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 299
A Specific Pattern of Somatic Mutations Associates with Poor Prognosis Aneuploid Acute Myeloid Leukemia: Results from the European NGS-PTL Consortium 290
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 289
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 289
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 283
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 274
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 273
Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy 271
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 265
c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in Chronic Myelogenous Leukemia CD34+ hematopoietic progenitor cells 260
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 257
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 252
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 251
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 249
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 248
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 244
Denaturing-HPLC-based assay for detection of ABL mutations in Chronic Myeloid Leukemia patients resistant to Imatinib 242
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 241
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 239
Adult B-Cell Precursor Acute Lymphoblastic Leukemia (BC-ALL) Negative For Recurrent Fusion Genes Are Characterized By a High Complex Genetic Heterogeneity Influencing Prognosis 239
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 233
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 230
Novel and rare fusion transcripts involving transcription factors and tumor suppressor genes in acute myeloid leukemia 230
Chromothripsis in AML patients: A new mechanism of cancer initiation and progression 227
ARF Loss, a Negative Prognostic Factor in Philadelphia-Positive Acute Lymphoblastic Leukemia, May Be Efficiently Overcome by the Small Molecule MDM2 Antagonist RG7112 226
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 226
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 224
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 224
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 219
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 219
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 218
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 214
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 211
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 209
The Novel Small Molecule Chk1/Chk2 Inhibitor PF-0477736 (Pfizer) Is Highly Active As Single Agent in Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) 209
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 208
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 208
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 207
Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment. 205
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 201
Ultra-deep sequencing (uds) allows more sensitive detection of the D816V and other kit gene mutations in systemic mastocytosis 201
c-Abl and Src-family kinases cross-talk in regulation of myeloid cell migration 200
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 200
Identification of Two DNMT3A Mutations Compromising Protein Stability and Methylation Capacity in Acute Myeloid Leukemia 200
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 199
IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia. 197
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 197
Novel Genomic Patterns of Metabolic Remodeling in Acute Myeloid Leukemia 196
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 195
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 194
Ultra-Deep Sequencing (UDS) Allows More Sensitive Detection of the D816V and Other Kit Gene Mutations in Systemic Mastocytosis 194
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy 194
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 192
Analisi di polimorfismi in geni coinvolti nel ciclo dei folati come determinanti di suscettibilità a leucemia mieloide cronica. 191
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 190
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr–Abl mutations and mutational analysis 187
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 187
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 186
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 186
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 186
Inhibition of DNA repair by the small molecule Chk1/Chk2 inhibitor PF-0477736 (Pfizer) in B-acute lymphoblastic leukemia (ALL) 185
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 183
Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. 183
Bellerophontes: an RNA-Seq data analysis framework for chimeric transcripts discovery based on accurate fusion model 183
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 182
Parallel single-cell metabolic analysis and extracellular vesicle profiling reveal vulnerabilities with prognostic significance in acute myeloid leukemia 180
Advances in the biology and therapy of chronic myeloid leukemia (CML): Proceedings from the 6(th) Post-ASH International CML and Myeloproliferative Neoplasms Workshop. 180
Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients 180
Backtracking BCR-ABL1 Mutants in Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Relapsing on Tyrosine Kinase Inhibitors with Deep Sequencing: Implications for Routine Mutation Testing 179
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 179
Association between transporters genotype and response to the treatment in a subset of previously untreated chronic myeloid leukemia patients enrolled into the tops trial. 176
Clec12a: A new AML stem cell-associated antigen 176
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 175
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 175
Clinical presentation and management practice of systemic mastocytosis. A survey on 460 Italian patients 175
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 175
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 174
A novel framework for chimeric transcript detection based on accurate gene fusion model 173
RNA Sequencing Reveals Novel and Rare Fusion Transcripts in Acute Myeloid Leukemia 173
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia 173
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 172
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 171
The Genomic and Transcriptomic Landscape of Systemic Mastocytosis 171
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 170
Combined Inhibition of Polo-like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells 169
CDC20 in and out of mitosis: a prognostic factor and therapeutic target in hematological malignancies 168
Coding sequence and intron-exon junctions of the c-myb gene are intact in the chronic phase and blast crisis stages of chronic myeloid leukemia patients 168
Down-Regulation of BMI-1 Is a New Marker of Sensitivity to Mdm2 Inhibition in B-Acute Lymphoblastic Leukemia. 168
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 167
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 167
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 166
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 166
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 165
Totale 21.792
Salva come PNG Salva come JPEG
Categoria #
all - tutte 135.070
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 135.070
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.583 0 0 0 0 0 0 0 0 0 218 300 2.065
2021/20226.022 693 142 393 462 625 419 105 423 299 397 1.027 1.037
2022/20236.567 762 1.055 347 821 462 476 282 350 1.057 148 534 273
2023/20241.674 68 289 95 163 114 412 99 106 68 77 83 100
2024/20256.575 243 1.156 621 460 832 314 522 195 91 612 288 1.241
2025/202614.845 1.189 1.731 1.550 1.071 1.785 888 1.501 593 3.440 1.097 0 0
Totale 52.031